We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Ismaila, Aisha![]() |
|
dc.contributor.author | Lawal, Ismaheel Opeyemi![]() |
|
dc.contributor.author | Popoola, Gbenga O.![]() |
|
dc.contributor.author | Mathebula, Matsontso![]() |
|
dc.contributor.author | Moagi, Ingrid![]() |
|
dc.contributor.author | Mokoala, Kgomotso M.G.![]() |
|
dc.contributor.author | Honest, Ndlovu![]() |
|
dc.contributor.author | Moeketsi, Nontando![]() |
|
dc.contributor.author | Nchabeleng, Maphoshane![]() |
|
dc.contributor.author | Hikuam, Chris![]() |
|
dc.contributor.author | Hatherill, Mark![]() |
|
dc.contributor.author | Fourie, P.B. (Petrus Bernardus)![]() |
|
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.date.accessioned | 2024-10-16T09:29:37Z | |
dc.date.available | 2024-10-16T09:29:37Z | |
dc.date.issued | 2024-12 | |
dc.description | DATA AVAILABILITY : No datasets were generated or analysed during the current study. | en_US |
dc.description.abstract | BACKGROUND : [18F]FDG-PET/CT is a sensitive non-invasive tool for assessing treatment response in patients with pulmonary tuberculosis. The data on the performance of [18F]FDG-PET/CT for response assessment among patients infected with the human immunodeficiency virus (HIV) is limited. Here, we investigated the differences between PET and CT lung findings on end-of-treatment [18F]FDG-PET/CT among HIV-positive versus HIV-negative patients who completed anti-tuberculous therapy for pulmonary tuberculosis. METHODS : Patients who completed anti-tuberculous therapy for pulmonary tuberculosis and declared cured based on negative clinical and laboratory assessments for active pulmonary tuberculosis were prospectively recruited to undergo [18F]FDG-PET/CT. Patients were classified as having residual metabolic activity if PET metabolic activity was demonstrated in the lung parenchyma or complete metabolic response if there was no abnormally increased [18F]FDG avidity in the lungs and compared the CT features. We identified 10 CT lung changes, five were associated with active pulmonary tuberculosis (nodules, micronodules in tree-in-bud pattern, consolidation, pleural effusion, and [18F]FDG-avid mediastinal/hilar lymphadenopathy) and the rest were associated with inactive sequelae of prior pulmonary tuberculosis (cysts, cavities, fibrosis, bronchiectasis, and calcifications and compared their incidence between HIV-positive and HIV-negative patients. RESULTS : Seventy-five patients were included with a mean age of 36.09 ± 10.49 years. There were fifty HIV-positive patients, all of whom were on antiretroviral therapy and with a median CD4 + T-cell of 255 cells/µL (IQR: 147–488). Fifteen HIV-positive patients had detectable HIV viremia with a median viral load of 12,497 copies/mL (IQR: 158–38,841). There was a significant difference in the incidence of residual metabolic activity and complete metabolic response between HIV-positive and HIV-negative patients. (P = 0.003) HIV-positive patients were more likely to have [18F]FDG-avid lymphadenopathy and HIV-negative patients had a higher incidence of cystic lung changes. The pattern of CT lung changes was otherwise not different between HIV-positive and HIV-negative patients. (P > 0.05) CONCLUSIONS : The incidence of residual metabolic activity and complete metabolic response on end-of-treatment [18F]F-FDG-PET/CT are similar between HIV-positive and HIV-negative patients. The incidence of [18F]FDG-avid mediastinal/hilar lymphadenopathy is more prevalent among HIV-positive patients. The pattern of lung changes was largely similar between HIV-positive and HIV-negative patients, indicating that the presence of HIV coinfection may not influence the interpretation of end-of-treatment [18F]F-FDG-PET/CT obtained for pulmonary tuberculosis treatment response assessment. | en_US |
dc.description.department | Medical Microbiology | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.librarian | hj2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | Open access funding provided by University of Pretoria. | en_US |
dc.description.uri | http://link.springer.com/journal/4033 | en_US |
dc.identifier.citation | Ismaila, A., Lawal, I.O., Popoola, G.O. et al. [18F]FDG PET and CT findings at therapy completion of pulmonary tuberculosis: comparison between HIV-positive and HIV-negative patients and impact on treatment response assessment. Clinical and Translational Imaging 2, 587–599 (2024). https://doi.org/10.1007/s40336-024-00641-4. | en_US |
dc.identifier.issn | 2281-5872 (print) | |
dc.identifier.issn | 2281-7565 (online) | |
dc.identifier.other | 10.1007/s40336-024-00641-4 | |
dc.identifier.uri | http://hdl.handle.net/2263/98616 | |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.rights | © The Author(s) 2024. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.subject | Pulmonary tuberculosis (PTB) | en_US |
dc.subject | [18F]FDG-PET/CT | en_US |
dc.subject | Residual metabolic activity | en_US |
dc.subject | Complete metabolic response | en_US |
dc.subject | HIV infection | en_US |
dc.subject | Human immunodeficiency virus (HIV) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | 18F-fluorodeoxyglucose (FDG) | en_US |
dc.subject | Positron emission tomography/computed tomography (PET/CT) | en_US |
dc.title | [18F]FDG PET and CT findings at therapy completion of pulmonary tuberculosis: comparison between HIV-positive and HIV-negative patients and impact on treatment response assessment | en_US |
dc.type | Article | en_US |